Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - concentrate for solution for infusion - atezolizumab 60 mg / 1 ml - urothelial carcinoma• tecentriq (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumours have a pd-l1 expression ≥ 5%.• tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.- non-small cell lung cancer •tecentriq, as a single agent, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have high pd-l1 expression (pd-l1 stained ≥ 50% of tumor cells [tc ≥ 50%] or pd-l1 stained tumor-infiltrating immune cells [ic] covering ≥ 10% of the tumor area [ic ≥ 10%]), as determined by an approved test, with no egfr or alk genomic tumor aberrations.•tecentriq, in combination with paclitaxel protein-bound and carboplatin,

Israel - English - Ministry of Health

bioavenir ltd, israel - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens.* children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no otheralternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; hypromellose; magnesium stearate; croscarmellose sodium; sucrose; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate sandoz is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes. fenofibrate sandoz is indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy. fenofibrate sandoz does not replace the appropriate control of blood pressure, blood glucose and blood lipids in reducing the progression of diabetic retinopathy.

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus - drugs used in diabetes - treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus, type 2 - drugs used in diabetes - rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methylprednisolone - tablets - methylprednisolone 4 mg - methylprednisolone - methylprednisolone - anti-allergic, anti-inflammatory for treatment of allergic conditions such as asthma and diverse skin disease, inflammatory states and arthritis.

European Union - English - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - nepafenac, quantity: 3 mg/ml - eye drops, suspension - excipient ingredients: carbomer 974p; carmellose sodium; benzalkonium chloride; boric acid; sodium hydroxide; hydrochloric acid; sodium chloride; propylene glycol; guar galactomannan; purified water; disodium edetate - ilevro is indicated for the:,- prevention and treatment of postoperative pain and inflammation associated with cataract surgery,- reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 1.65 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),- the treatment of visual impairment due to diabetic macular oedema (dme),- the treatment of proliferative diabetic retinopathy (pdr),- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo)

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: histidine; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; water for injections - lucentis (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd), ? the treatment of visual impairment due to diabetic macular oedema (dme), ? treatment of proliferative diabetic retinopathy (pdr), ? the treatment of visual impairment due to choroidal neovascularisation, ? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), ? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,lucentis is indicated in preterm infants for:,? the treatment of retinopathy of prematurity (rop) with zone i (stage 1+, 2+, 3 or 3+), zone ii (stage 3+) or ap-rop (aggressive posterior rop) disease.